CLINICAL TRIALS AND OBSERVATIONS Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
نویسندگان
چکیده
Philipp le Coutre,1 Oliver G. Ottmann,2 Francis Giles,3 Dong-Wook Kim,4 Jorge Cortes,3 Norbert Gattermann,5 Jane F. Apperley,6 Richard A. Larson,7 Elisabetta Abruzzese,8 Stephen G. O’Brien,9 Kazimierz Kuliczkowski,10 Andreas Hochhaus,11 Francois-Xavier Mahon,12 Giuseppe Saglio,13 Marco Gobbi,14 Yok-Lam Kwong,15 Michele Baccarani,16 Timothy Hughes,17 Giovanni Martinelli,16 Jerald P. Radich,18 Ming Zheng,19 Yaping Shou,19 and Hagop Kantarjian3
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
1M. D. Anderson Cancer Center, Houston, TX; 2Universitaetsklinikum Duesseldorf, Duesseldorf, Germany; 3H. Lee Moffitt Cancer Center, Tampa, FL; 4Azienda Policlinico Umberto I–Universita La Sapienza, Rome, Italy; 5S. Orsola–Malpighi University Hospital, University of Bologna, Bologna, Italy; 6Vrije University (VU) Medisch Centrum, Amsterdam, the Netherlands; 7Hópital Edouard Herriot, Lyon, Franc...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether scoring mutation based on in vitro inhibitory concentration of each TKI-mutation pair can predict lo...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous leukemia (CML), with a high proportion of patients achieving complete cytogenetic responses (CCRs). However, it is not clear whether remissions will be durable and whether imatinib mesylate can eliminate the malignant primi...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)
The Abl kinase inhibitor imatinib mesylate (STI571) has significant and rapid antileukemic activity in Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia (Ph ALL) but such activity is usually of short duration except for a small proportion of patients. To determine the prognostic significance of early Bcr-Abl levels and changes in peripheral blood (PB) and bone marrow (BM), s...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias
The translocation (9;22) gives rise to the p190Bcr-Abl and p210Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph ) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We c...
متن کامل